Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine by Folschweiller, Nicolas et al.
B R I E F  R E P O R T
The Journal of Infectious Diseases
BRIEF REPORT • jid 2019:219 (1 june) • 1799
 
Received 13 November 2018; editorial decision 18 December 2018; accepted 8 January 2019; 
published online February 3, 2019.
Presented in part: 36th Annual Meeting of the European Society for Paediatric Infectious 
Diseases, Malmö, Sweden, 29 May–2 June 2018.
Correspondence: N.  Folschweiller,  PhD, GSK, Avenue Fleming 20, 1200 Wavre, Belgium 
(Nicolas.x.folschweiller@gsk.com).
The Journal of Infectious Diseases®  2019;219:1799–1803
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society 
of America. This is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted 
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
DOI: 10.1093/infdis/jiy743
Long-term Cross-reactivity Against 
Nonvaccine Human Papillomavirus 
Types 31 and 45 After 2- or 3-Dose 
Schedules of the AS04-Adjuvanted 
Human HPV-16/18 Vaccine 
Nicolas Folschweiller,1,  Ulrich Behre,2 Marc Dionne,6 Paolo Durando,10,11  
Susanna Esposito,12 Linda Ferguson,7 Murdo Ferguson,7 Peter Hillemanns,3  
Shelly A. McNeil,8 Klaus Peters,4 Brian Ramjattan,9 Tino F. Schwarz,5  
Khuanchai Supparatpinyo,13 Pemmaraju V. Suryakirian,14 Michel Janssens,1  
Philippe Moris,1 Annabelle Decreux,1 Sylviane Poncelet,1 and Frank Struyf1
1GSK, Wavre, Belgium; 2Hauptstrasse 240, Kehl Baden-Württemberg, 
3MedizinischeHochschule Hannover; Hannover, 4BernerHeerweg 157, Hamburg, and 
5Institute of Laboratory Medicine and Vaccination Centre, Klinikum Würzburg Mitte, Standort 
Juliusspital, Würzburg, Germany; 6Centre Hospitalier Universitaire, Québec, 7Colchester 
Research Group, Truro, 8Canadian Center for Vaccinology, IWK Health Centre and Nova 
Scotia Health Authority, Dalhousie University, Halifax, and 9First Line Medical Services, St. 
John’s, Canada; 10Department of Health Sciences, University of Genoa, and 11IRCCS Ospedale 
Policlinico AOU San Martino-IST, Genoa, and 12Pediatric Clinic, Department of Surgical and 
Biomedical Sciences, Università degli Studi di Perugia, Perugia, Italy; 13Chiang Mai University, 
Thailand; and 14GSK, Bangalore, India
This analysis focused on long-term cross-reactive immunoge-
nicity against nonvaccine human papillomavirus (HPV) types 
31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 
vaccine in girls aged 9–14 years or following 3 doses in women 
aged 15–25  years, for up to 3  years (HPV-070 study) and up 
to 5  years (HPV-048 study) after the first vaccination. Both 
schedules elicited antibodies against HPV-31 and HPV-45 up 
to 5 years after first dose. The antibody concentration was sim-
ilar in young girls as compared to women. Specific CD4+ T-cell 
and B-cell responses to HPV-31 and HPV-45 at month 36 were 
similar across groups. Clinical trials registration: NCT01381575 
and NCT00541970.
Keywords. AS04-HPV-16/18 vaccine; HPV-31; HPV-45; 
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The AS04-adjuvanted human papillomavirus (HPV) types 
16 and 18 vaccine (hereafter, “AS04–HPV-16/18”) was devel-
oped and initially licensed for delivery on a 3-dose schedule, 
at months 0, 1, and 6. AS04 is an adjuvant system containing 
3-O-desacyl-4’-monophosphoryl lipid A (50 μg; GSK) adsorbed 
on aluminum salt (500  μg  Al3+). The high immunogenicity 
of the vaccine observed after 3 doses in girls aged 9–14 years 
led to the investigation and eventual licensure of a 2-dose 
schedule, at months 0 and 6, in this age group. The aim of the 
exploratory phase 1/2 HPV-048 study (clinical trials registra-
tion NCT00541970) was to investigate alternative schedules 
of AS04–HPV-16/18 in subjects aged 9–25 years [1]. The con-
firmatory phase 3 HPV-070 study (clinical trials registration 
NCT01381575) aimed at demonstrating the noninferiority of 
the immune response of the 2-dose schedule (at months 0 and 
6)  in young girls (age, 9–14 years) versus the 3-dose schedule 
(at months 0, 1, and 6) in young women (age, 15–25 years) [2], 
the age group in which AS04–HPV-16/18 efficacy against cer-
vical intraepithelial neoplasia grade 3 or greater was previously 
demonstrated [3].
Even if HPV-16 and HPV-18, detected in 70% of cases, are 
the most common types associated with cervical cancer [4], 
HPV-31 and HPV-45 are also high-risk HPV types, leading 
to approximately 10% of all cervical cancer cases [5]. Efficacy 
and immunogenicity studies with 3 doses of AS04–HPV-16/18 
have shown a degree of protection (cross-protection) [3, 6] 
and immunogenicity (cross-reactivity) [7] against nonvaccine 
HPV types, including HPV-31 and HPV-45. Recent evidence 
provided by follow-up studies showed long-term cross-protec-
tive effectiveness after 3 doses [8–11]. In addition to the vac-
cine types (ie, HPV-16/18), the HPV-070 and HPV-048 studies 
also investigated the cellular and humoral immunogenicity of 
AS04–HPV-16/18 against the nonvaccine HPV types 31 and 
45 after 2 doses of the vaccine. Here, we disclose HPV-31 and 
HPV-45 immunogenicity results from the HPV-048 and HPV-
070 studies, along with cellular immune responses from the 
HPV-070 study.
METHODS AND PARTICIPANTS
Study Design, Participants, and Ethics
The HPV-048 (clinical trials registrationNCT00541970) study 
was a phase 1/2, partially blinded, controlled, randomized 
(1:1:1:1), parallel group trial conducted at 21 centers in Canada 
and Germany between October 2007 and March 2013. Study 
HPV-070 (clinical trials registration NCT01381575)  was a 
phase 3b, multicenter, open-label, randomized trial conducted 
in 5 countries (Canada, Germany, Italy, Taiwan, and Thailand) 
between June 2011 and November 2014.
The methods of these studies have been described and pub-
lished previously [1, 2]. A subset of subjects from both studies 
was evaluated for the current analysis. All subjects included in 
the HPV-048 trial and with samples available at the required 
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time points were selected. The 50 first subjects in each age 
stratum (9–11, 12–14, 15–19, and 20–25  years) from prese-
lected sites were included in the HPV-070 study. The subjects 
in the humoral immunity subset were the same as those in 
the cell-mediated immunity subcohort in the HPV-070 study. 
Immunogenicity data were assessed up to 5  years after first 
vaccination in the HPV-048 study and for up to 3 years after 
first vaccination, along with cellular immune responses, in the 
HPV-070 study.
Both primary studies were approved by an appropriate inde-
pendent ethics committee or institutional review board and 
conducted according to the principles of the Declaration of 
Helsinki, good clinical practice guidelines, and all other regu-
latory requirements. Written informed consent was obtained 
from all participants and/or parents or legal representatives 
prior the start of the study.
Immunogenicity Assessments
Blood samples for antibody determination were collected from 
all subjects before the first vaccination (at month 0); at months 
7, 12, 18, 24, and 36; and at months 48 and 60 (in the HPV-048 
study only). Antibodies to HPV-31 and HPV-45 were assessed 
by an enzyme-linked immunosorbent assay (ELISA) as pre-
viously described [7]. Seroconversion was defined as a serum 
antibody titer greater than or equal to the cutoff of 59 ELISA 
units/mL among subjects seronegative to HPV-31 and HPV-45 
before vaccination.
In the HPV-070 study, CD4+ T-cell responses specific to 
HPV-31 and HPV-45 were determined by intracellular cytokine 
staining, as described elsewhere [7]. B-cell responses to HPV-31 
and HPV-45 were evaluated by a B-cell enzyme-linked immu-
nosorbent spot assay, as previously described [12].
Statistical Methods
The descriptive primary analyses were performed on the initially 
seronegative participants in the month 36 (for the HPV-070 study) 
and month 60 (for the HPV-048 study) according-to-protocol 
(ATP) cohorts for immunogenicity (ATP-I); secondary immuno-
genicity analyses based on the total vaccinated cohort (TVC) were 
performed to complement the ATP analyses. The analysis was 
exploratory for the HPV-070 study, and testing and analysis were 
conducted in a post hoc fashion for the HPV-048 study. The ATP-I 
included all evaluable participants who met all eligibility criteria, 
who complied with the study procedures, and for whom data con-
cerning immunogenicity end point measures were available.
Geometric mean concentration (GMC) calculations were 
performed by taking the antilog of the mean of the log concen-
tration transformations. Seroconversion rates for each antigen 
and GMC were calculated with exact 95% confidence intervals 
(CIs) before and after vaccination. An arbitrary value of half the 
cutoff for the GMC calculation was given to antibody concen-
trations below the assay cutoff.
RESULTS
Study Population
In the HPV-048 study, 960 participants received at least 1 vaccine 
dose and were included in the TVC. Among them, AS04–HPV-
16/18 was administered to 157 participants aged 15–25 years (and 
82 participants aged 9–14 years) via the standard 3-dose sched-
ule and to 78 participants aged 9–14 years (and 162 participants 
aged 15–25 years) via the 2-dose schedule. The other participants 
(n = 481) received a different vaccine formulation. There were 91 
participants aged 15–25 years in the 3-dose group and 46 partic-
ipants aged 9–14 years in the 2-dose group who were included in 
the month 60 ATP-I; of these, 37 and 33 participants, respectively, 
were considered for the HPV-31 and HPV-45 subset analysis [1].
Overall, 967 participants in the HPV-070 TVC (93.7%) 
received AS04–HPV-16/18 and completed the month 36 visit. 
Among them, 907 (93.8%) were included in the month 36 ATP-I 
cohort: 401 were aged 15–25 years and in the 3-dose group, and 
506 were aged 9–14 years and in the 2-dose group [2]. Of these 
participants, 92 and 96, respectively, were considered for the 
HPV-31 and HPV-45 subset analysis
Demographic characteristics and baseline serostatus, 
stratified by age and study, are shown for both groups in 
Supplementary Table 1.
Immune Response to HPV-31 and HPV-45
All seronegative participants from the HPV-048 study and all 
but 1 (in the 3-dose group) from the HPV-070 study in the 
ATP-I seroconverted to HPV-31 and HPV-45 one month after 
the last vaccine dose (at month 7; Supplementary Table 2). At 
month 60 in the HPV-048 ATP-I cohort, similar proportions of 
subjects were seropositive for HPV-31 and for HPV-45 among 
those vaccinated with the 2-dose and 3-dose schedules: about 
90% of subjects were seropositive for HPV-31, and 80.0% were 
seropositive for HPV-45. Similarly, at month 36 in the HPV-
070 ATP-I cohort, about 80% of vaccinees were seropositive for 
HPV-31 and for HPV-45, irrespective of the group.
After a peak response at month 7, GMCs of HPV-31 and 
HPV-45 antibodies started reaching a plateau phase by month 
24 in both studies, which was sustained until month 60 in the 
HPV-048 study (Figure 1). GMCs for HPV-31/45 antibodies 
were similar in young girls receiving the 2-dose schedule as 
compared to young adult women receiving the 3-dose schedule 
(Supplementary Table 3).
Results in the TVC were in line with those observed in the 
ATP-I (data not shown).
HPV-31– and HPV-45–Specific B-Cell and T-Cell Responses
HPV-31– and HPV-45–specific memory B-cell and T-cell 
responses were detected following vaccination and were simi-
lar across groups (Figure 2 and Supplementary Table 4). Similar 
results as those described above were found in the TVC (data 
not shown).
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DISCUSSION
In both studies, similar anti–HPV-31 and anti–HPV-45 
GMCs and seroconversion rates were observed in young 
girls receiving the 2-dose schedule as compared to young 
adult women receiving the 3-dose schedule, with >80.0% of 
subjects who were initially seronegative seroconverting fol-
lowing vaccination, irrespective of the schedule received. 
The kinetics of antibodies against nonvaccine HPV types 31 
and 45 observed in both trials were similar to that observed 
against HPV-16 and HPV-18 [2, 13]: there was a peak re-
sponse after the last vaccine dose, followed by a plateau, with 
no sign of waning immunogenicity. As expected, GMCs for 
HPV-31 and HPV-45 appeared to be lower than those for 
HPV-16 and HPV-18 at similar time points, although GMCs 
for different types should not be directly compared because 
they result from separate assays using different arbitrary units 
(Supplementary Table 5).
HPV-31– and HPV-45–specific CD4+ T cells and memory 
B-cell responses were detected until the end of the HPV-070 
study, at month 36, and in similar range across groups. This 
suggests the ability to produce antibodies against HPV-31 and 
HPV-45 after challenge or natural infection years after primary 
vaccination with either a 2-dose or 3-dose schedule. These find-
ings were not surprising, because HPV-31 is closely related to 
HPV-16 and HPV-45 is closely related to HPV-18. However, 
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Figure 1.  Human papillomavirus type 31 (HPV-31; A) and HPV-45 (B) geometric mean concentrations (GMCs) by enzyme-linked immunosorbent assay at each time point for 
initially seronegative subjects in the month 36 (for the HPV-070 study) or month 60 (for the HPV-048 study) according-to-protocol cohort for immunogenicity. CI, confidence 
interval; 2D, 2-dose schedule of the AS04-adjuvanted HPV-16/18 vaccine; 3D, 3-dose schedule of the AS04-adjuvanted HPV-16/18 vaccine. aThe GMC at month 0 was equal 
to half of the assay cutoff (29.5 ELISA units/mL).
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to an aluminum-only adjuvanted HPV vaccine, the amplitude 
of cross-reactivity was much bigger with the AS04-adjuvanted 
vaccine. We hypothesize that the adjuvant plays a major role 
in the production of nonvaccine-type anti-HPV antibodies [7].
Overall, these results provide additional evidence that the 
cross-protection against HPV-31 and HPV-45 after vaccination 
with either 2 doses or 3 doses of AS04–HPV-16/18 is likely to 
be sustained whether the vaccine is given as a 2-dose or a 3-dose 
schedule.
Our present work has the limitation that no efficacy end 
points were assessed along with the immunogenicity assess-
ment, owing to the young age of the population studied. 
However, long-term cross-protection after 3 doses of AS04–
HPV-16/18 against HPV-31 and HPV-45, as well as other HPV 
types, was shown in clinical trials [6] and effectiveness/impact 
studies [8–11]. Our results suggest that a similar outcome can 
be expected after 2 doses of the vaccine in young girls.
In summary, cross-reactivity against HPV-31 and HPV-45 
is maintained over time and is similar following either 2 doses 
of AS04–HPV-16/18 in girls or 3 doses in women. The GMC 
plateau phase observed up to 5 years after vaccination and the 
presence of memory B cells bring additional evidence that the 
cross-protection offered by 2 doses of the AS04–HPV-16/18 
against nonvaccine types 31 and 45 is long-lasting.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
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Figure 2. Human papillomavirus type 31 (HPV-31)–specific (A) and HPV-45–specific (B) CD4+ T-cell responses and HPV 31–specific (C) and HPV-45–specific (D) memory 
B-cell responses for initially seronegative subjects from the HPV-070 study who were in the month 36 according-to-protocol cohort for immunogenicity. Upper and lower limits 
of boxes denote interquartile ranges, horizontal lines inside boxes and bars denote median values, and whiskers denote maximum and minimum values. 2D, 2-dose schedule 
of the AS04-adjuvanted HPV-16/18 vaccine; 3D, 3-dose schedule of the AS04-adjuvanted HPV-16/18 vaccine.
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